Efficacy analysis of S-1 plus nedaplatin versus standard second-line chemotherapy in the treatment of advanced lung adenocarcinoma that failure in the first-line chemotherapy
- VernacularTitle:替吉奥联合奈达铂对比标准二线化疗用于一线化疗失败的中晚期肺腺癌的疗效分析
- Author:
Zhaoguo XU
;
Xiaoye ZHANG
;
Xiaoying QI
;
Li YU
- Publication Type:Journal Article
- Keywords:
non-small cell lung adenocarcinoma;
S-1;
nedaplatin
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(3):78-80
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of S-1 plus nedaplatin and standard second-line chemotherapy in the treatment of advanced lung adenocarcinoma that failure in the first-line chemotherapy.Methods A total of 95 cases with IIIb-IV stage non-small cell lung adenocarcinoma that failure in the first-line chemotherapy was included in this paper and divided into two groups:group A(n=5 1 )was treated with S-1 combined with nedaplatin chemotherapy;group B(n=44)was treated with pemetrexed or docetaxel single-agent chemotherapy,21 days were a cycle of treatment,and totally 4 cycles of chemotherapy. Results The objective response rates(CRR)in group A and group B were 33.0% and 19.3%respectively(P<0.05),and the difference was significant;the clinical benefit rates(CBR)in two groups were 57. 1% and 40.9% respectively (P <0.05 ),and there was significant difference between two groups. The median perfect forward secrecy(PFS)was 99 days and 40 days respectively,and the difference between two groups was significant(P<0.05 ). The one-year survival rates in groups A and B were 5 1.3% and 33.7%(P<0.05 ),and there was significant difference(P<0.05 ). Logistic multi-factor regression analysis showed that the ORR and CER had no correlation with the gender, age, proportion score (PS )and the first-line chemotherapy selection. Conclusion S-1 plus nedaplatin chemotherapy is better than the standard second-line chemotherapy in the treatment of advanced lung adenocarcinoma that failure in the first-line chemotherapy,with the advantage of good tolerance,and it can provide a new choice for the treatment of advanced non-small cell lung adenocarcinoma.
